Artelo Biosciences (ARTL) Stock Price, News & Analysis

Company Overview

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics that target the endocannabinoid system, a network of receptors and signaling pathways involved in processes such as pain, inflammation, appetite and immune response. The company is headquartered in San Diego, California, and its research and development activities are directed toward pharmaceutical applications of cannabinoid biology rather than consumer cannabis products.

Artelo’s pipeline has included ART27.13, a peripherally restricted cannabinoid receptor agonist being evaluated for conditions associated with appetite loss and cancer-related cachexia. The company has also developed ART12.11, a proprietary cannabidiol-based cocrystal intended for potential use in oncology, including glioblastoma, and ART26.12, a fatty acid amide hydrolase inhibitor being investigated for pain and cancer-related applications. Development programs and indications may change as clinical and regulatory work progresses.

The company was established to advance cannabinoid-based medicines through preclinical and clinical development and has worked with academic and commercial partners to support its programs. Artelo Biosciences is led by President and Chief Executive Officer Gregory D. Gorgas. Its therapeutic programs are intended for international pharmaceutical markets, although the company’s principal operations and corporate base are in the United States.

Key Stats

• Today's Range: $3.92 to $4.14
• 50-Day Range: $3.75 to $10.44
• 52-Week Range: $3.45 to $179.19
• Volume: 29,354 shs
• Average Volume: 93,046 shs
• Market Capitalization: $2.17 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Reduce

Artelo Biosciences Stock Analysis - MarketRank™

Artelo Biosciences scored higher than 11% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Reduce

Consensus Rating

Artelo Biosciences has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Artelo Biosciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Artelo Biosciences is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Artelo Biosciences is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.78% of the float of Artelo Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Artelo Biosciences has a short interest ratio ("days to cover") of 0.23, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Artelo Biosciences has recently decreased by 57.90%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Artelo Biosciences does not currently pay a dividend.

Dividend Growth

Artelo Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: -0.08

News Sentiment

Artelo Biosciences has a news sentiment score of -0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Artelo Biosciences this week, compared to 3 articles on an average week.

MarketBeat Follows

1 people have added Artelo Biosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Artelo Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.20% of the stock of Artelo Biosciences is held by insiders.

Percentage Held by Institutions

0.87% of the stock of Artelo Biosciences is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 9/20/2026
• Next Earnings (Estimated): 11/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ARTL
• CIK: 1621221
• Web: www.artelobio.com
• Phone: (858) 925-7049
• Fax: N/A
• Employees: 7
• Year Founded: 2017

Profitability

• EPS (Trailing Twelve Months): ($151.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.88 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -518.27%
• Return on Assets: -194.29%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.00
• Quick Ratio: 3.00

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($17.03) per share
• Price / Book: -0.23

Miscellaneous

• Outstanding Shares: 550,000
• Free Float: 530,000
• Market Cap: $2.17 million
• Optionable: Not Optionable
• Beta: -0.07